Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NEW JCM GROUP
300157
5
Shenzhen S-king Intelligent Equipment
688328
US OptionsDetailed Quotes
PFE250425P33000
- 10.64
- 0.000.00%
15min DelayClose Apr 25 15:59 ET
0.00High0.00Low
10.64Open10.64Pre Close0 Volume0 Open Interest33.00Strike Price0.00Turnover8040.22%IV2.44%PremiumApr 25, 2025Expiry Date10.08Intrinsic Value100Multiplier-2DDays to Expiry0.56Extrinsic Value100Contract SizeAmericanOptions Type-0.9733Delta0.0150Gamma2.27Leverage Ratio-64.5267Theta0.0000Rho-2.21Eff Leverage0.0000Vega
Pfizer Newsroom
Earnings Preview: Pfizer to Report Financial Results on April 29
Market Technical Analysis: Will the US Stock Market's Rebound Ignite Your Next Trade?
Reported Saturday, Pfizer's Sasanlimab Combination Therapy Shows Strong Event-Free Survival Gains In High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Express News | Pfizer : HSBC Cuts Target Price to $27 From $35
Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025
Pfizer Announces Phase 3 CREST Trial Met Primary Endpoint of EFS
Pfizer Inc. (PFE): Among Billionaire Ken Fisher's Healthcare Stock Picks With Massive Upside Potential
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
1 Stock to Buy, 1 Stock to Sell This Week: Meta Platforms, Pfizer
Earnings Week Ahead: MSFT, AAPL, META, AMZN, QCOM, PFE, MA, V, PYPL, ROKU, MCD, SBUX, KO, and More
Express News | Pfizer Inc - Trial Meets Primary Endpoint With Sasanlimab Combination
Express News | Pfizer Inc - Results Shared With Global Health Authorities for Regulatory Filings
Express News | Pfizer Inc - Phase 3 Crest Trial Shows 32% Risk Reduction With Sasanlimab
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Express News | Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in Bcg-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer's Stock Outlook: Analysts Weigh In on Future Prospects
Headache For MOH With Trump's Flip-Flop On Pharma Tariff
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Novavax Told by FDA to Conduct Additional Study for COVID Vaccine - Report
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now